Murat Cokol
Murat Cokol
Axcella Health
Verified email at axcellahealth.com
Title
Cited by
Cited by
Year
The genetic landscape of a cell
M Costanzo, A Baryshnikova, J Bellay, Y Kim, ED Spear, CS Sevier, ...
science 327 (5964), 425-431, 2010
22152010
Finding nuclear localization signals
M Cokol, R Nair, B Rost
EMBO reports 1 (5), 411-415, 2000
8182000
Harnessing connectivity in a large-scale small-molecule sensitivity dataset
B Seashore-Ludlow, MG Rees, JH Cheah, M Cokol, EV Price, ME Coletti, ...
Cancer discovery 5 (11), 1210-1223, 2015
3962015
Systematic exploration of synergistic drug pairs
M Cokol, HN Chua, M Tasan, B Mutlu, ZB Weinstein, Y Suzuki, ME Nergiz, ...
Molecular systems biology 7 (1), 544, 2011
2662011
A protein domain-based interactome network for C. elegans early embryogenesis
M Boxem, Z Maliga, N Klitgord, N Li, I Lemmens, M Mana, ...
Cell 134 (3), 534-545, 2008
2172008
Strength of selection pressure is an important parameter contributing to the complexity of antibiotic resistance evolution
T Oz, A Guvenek, S Yildiz, E Karaboga, YT Tamer, N Mumcuyan, VB Ozan, ...
Molecular biology and evolution 31 (9), 2387-2401, 2014
2032014
Oxidative Stress Is a Mediator for Increased Lipid Accumulation in a Newly Isolated Dunaliella salina Strain
K Yilancioglu, M Cokol, I Pastirmaci, B Erman, S Cetiner
PloS one 9 (3), e91957, 2014
2022014
Retraction rates are on the rise
M Cokol, F Ozbay, R Rodriguez‐Esteban
EMBO reports 9 (1), 2-2, 2008
1342008
Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives
KC Bulusu, R Guha, DJ Mason, RPI Lewis, E Muratov, YK Motamedi, ...
Drug discovery today 21 (2), 225-238, 2016
1292016
How many scientific papers should be retracted?
M Cokol, I Iossifov, R Rodriguez‐Esteban, A Rzhetsky
EMBO reports 8 (5), 422-423, 2007
802007
Emergent behavior of growing knowledge about molecular interactions
M Cokol, I Iossifov, C Weinreb, A Rzhetsky
Nature biotechnology 23 (10), 1243-1247, 2005
742005
Efficient measurement and factorization of high-order drug interactions in Mycobacterium tuberculosis
M Cokol, N Kuru, E Bicak, J Larkins-Ford, BB Aldridge
Science advances 3 (10), e1701881, 2017
642017
Chemogenomics and orthology‐based design of antibiotic combination therapies
S Chandrasekaran, M Cokol‐Cakmak, N Sahin, K Yilancioglu, H Kazan, ...
Molecular systems biology 12 (5), 872, 2016
612016
A parallel adder coordinates mycobacterial cell-cycle progression and cell-size homeostasis in the context of asymmetric growth and organization
MM Logsdon, PY Ho, K Papavinasasundaram, K Richardson, M Cokol, ...
Current Biology 27 (21), 3367-3374. e7, 2017
412017
Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α
C Ceran, M Cokol, S Cingoz, I Tasan, M Ozturk, T Yagci
BMC cancer 12 (1), 1-16, 2012
382012
Temporal and intrinsic factors of rifampicin tolerance in mycobacteria
K Richardson, OT Bennion, S Tan, AN Hoang, M Cokol, BB Aldridge
Proceedings of the National Academy of Sciences 113 (29), 8302-8307, 2016
322016
Large-scale identification and analysis of suppressive drug interactions
M Cokol, ZB Weinstein, K Yilancioglu, M Tasan, A Doak, D Cansever, ...
Chemistry & biology 21 (4), 541-551, 2014
282014
Prediction of ultra-high-order antibiotic combinations based on pairwise interactions
I Katzir, M Cokol, BB Aldridge, U Alon
PLoS computational biology 15 (1), e1006774, 2019
262019
Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma
V Jeannot, B Busser, L Vanwonterghem, S Michallet, S Ferroudj, M Cokol, ...
OncoTargets and therapy 9, 6843, 2016
262016
Synthesis and characterization of amino acid-functionalized calcium phosphate nanoparticles for siRNA delivery
F Bakan, G Kara, MC Cakmak, M Cokol, EB Denkbas
Colloids and Surfaces B: Biointerfaces 158, 175-181, 2017
252017
The system can't perform the operation now. Try again later.
Articles 1–20